Connect your AI

Spectral AI, Inc. MDAI Acquired in-process research and development

Acquired in-process research and development at other companies

CTO

Citius Oncology, Inc.CTOR

$40M+2,393%

MAG

MagneraMAGN

$5M+53.8%

Smith & Wesson Brands, Inc.SWBI

$0—

NVE CorporationNVEC

$771.2K-25.8%

Erasca, Inc.ERAS

$150M—

Relmada Therapeutics, Inc.RLMD

$8.09M-32.3%

Other financials

Income statement

Revenue$4.0M-40.5%

Gross profit$2.0M-36.0%

Operating income-$2.0M-120%

Net income-$3.4M-218%

EPS (diluted)-$0.11-200%

Balance sheet

Cash & equivalents$11.7M-17.1%

Total debt$6.0M-36.6%

Total equity-$8.8M-442%

Total assets$17.7M-14.4%

Cash flow

Operating cash flow-$3.7M-148%

Valuation

Market cap$55.06M+3.9%

Enterprise value$49.43M-4.8%

P/S3.3×+1.3×

Profitability

Gross margin46%+0.9pp

Operating margin-57.2%-104pp

Net margin-70%+176pp

Returns & leverage

Return on equity-255.5%—

Debt / equity0.7×+0.7×

Current ratio0.8×-0.7×

Where this comes from

Reported directly by Spectral AI, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Spectral AI, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spectral AI, Inc.'s acquired in-process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Spectral AI, Inc.'s acquired in-process research and development?: Spectral AI, Inc. (MDAI) reported acquired in-process research and development of $2M in Q1 2026.
How has Spectral AI, Inc.'s acquired in-process research and development changed year-over-year?: Spectral AI, Inc.'s acquired in-process research and development decreased by 44.4% year-over-year, from $3.6M to $2M.